Company profile
Dia Beta Labs Ltd Target-Led Management of Metabolic Disease
Dia Beta Labs Ltd is a UK company with status active founded in 2022 based in Northern Ireland.
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
PSC08 | Transaction MzQzODU4MTcwNmFkaXF6a2N4
Published 07 Oct 2024 11:12
RESOLUTIONS | Transaction WURDVUtVRU9hZGlxemtjeA | Paper/PDF filed
Published 04 Oct 2024 12:35
MA | Transaction MzQzODEzMTQ1NGFkaXF6a2N4 | Paper/PDF filed
Published 04 Oct 2024 01:07
PSC07 | Transaction MzQzODI2NTgxMWFkaXF6a2N4
Published 03 Oct 2024 08:31
PSC07 | Transaction MzQzNzk4NzI3OGFkaXF6a2N4
Published 01 Oct 2024 04:03
SH01 | Transaction MzQzNzk4NzAyNGFkaXF6a2N4
Published 01 Oct 2024 04:01
SH08 | Transaction MzQzNzU2ODkzMGFkaXF6a2N4 | Paper/PDF filed
Published 01 Oct 2024 06:46
RESOLUTIONS | Transaction WURDSktHWDVhZGlxemtjeA | Paper/PDF filed
Published 01 Oct 2024 06:43
SH02 | Transaction MzQzNzU2ODgyN2FkaXF6a2N4 | Paper/PDF filed
Published 01 Oct 2024 06:39
SH10 | Transaction MzQzNzU2ODk1MGFkaXF6a2N4 | Paper/PDF filed
Published 01 Oct 2024 06:34
SH01 | Transaction MzQzNzU2ODg3MGFkaXF6a2N4
Published 27 Sep 2024 07:07
Company registered at Companies House
1 May 2025 to 31 Oct 2026
Dia Beta Labs (DBL) is a **UK-based biotech company** devoted to **tackling the worsening global metabolic disease crisis**, which is driven by uncurbed growth of obesity and diabetes. DBL has developed selective lead molecules against its lead target, a novel receptor in metabolic disease. Our data to date indicates that our leads have the potential to *...
1 Oct 2024 to 31 Mar 2026
Dia Beta Labs (DBL) is a Northern Ireland-based biotech company **devoted to tackling the worsening global metabolic disease crisis**, driven by uncurbed growth of obesity and diabetes. **DBL has uncovered a novel disease target in metabolic disease** which is selectively activated by our current lead molecule, DBL002\. Our data indicates **DBL002 has the...
1 Apr 2024 to 30 Apr 2025
Dia Beta Labs (DBL) is a **Northern-Ireland based biotech company** committed to tackling the worsening metabolic disease crisis sweeping the globe, driven by uncurbed prevalence of obesity and diabetes. DBL has uncovered a **novel disease target** in metabolic disease which is effectively exploited by our current lead molecule, DBL002\. Our data to date ...
1 Oct 2022 to 31 Mar 2024
Dia Beta Labs are a UK-based biopharmaceutical company focused on the development of novel treatments for Type 2 diabetes mellitus and obesity. Dia Beta Labs builds on over 30 years of academic success from its founding research group, the Diabetes Research Group (DRG) at Ulster University, Northern Ireland. Diabetes occurs when the pancreas does not prod...
